Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rebonuputemcel - DiscGenics

Next Previous
Search
Drug Profile

Rebonuputemcel - DiscGenics

Alternative Names: IDCT; IDCT-001; Injectable discogenic cell therapy - DiscGenics

Latest Information Update: 22 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DiscGenics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intervertebral disc degeneration
  • No development reported Spinal disorders

Most Recent Events

  • 16 Jul 2024 DiscGenics plans to file biologics license application (BLA) with US FDA in USA for Intervertebral disc degeneration
  • 16 Jul 2024 DiscGenics receives approval from the US FDA for Rebonuputemcel for phase-III (PIVOT and CONFIRM) trial in Intervertebral disc degeneration
  • 16 Jul 2024 DiscGenics plans phase-III (DGX-A02 or PIVOT) trial for Intervertebral disc degeneration in USA in Q4 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top